Are your patients ready to embrace change?
January 1st 2007Happy New Year to you all. I'm sure, by now, the memories of Christmas have faded and the New Year's resolutions have already been broken but I do hope you used the holiday season to recharge your batteries, ready to face whatever 2007 may bring.
The new versus the old: local anaesthesia techniques examined
December 12th 2006A survey of British Ophthalmologists has found that there is a lower rate of serious complications after cataract surgery if sub–Tenon's, topical and topical–intracameral local anaesthesias are used rather than the "older" retrobulbar and peribulbar techniques.
Evaluating the risk and progression of glaucoma: easier said than done
November 14th 2006More prospective studies are needed to evaluate the role of diurnal and long-term intraocular pressure (IOP) function in glaucoma development and progression, according to Felipe A. Medeiros, MD, PhD, assistant professor of ophthalmology, University of California at San Diego, USA, speaking at the glaucoma subspecialty session.
Oral therapy the right choice for infections
November 14th 2006Oral antiviral medications offer an effective, more convenient option compared with topical antiviral therapy for patients with acute infectious ulcers associated with herpes simplex keratitis. Oral treatment increases the likelihood of therapy adherence, according to Deborah P. Langston, MD, FACS, speaking at the eye infection symposium.
Debating the importance of blue light filtering
November 14th 2006Blue light filtering intraocular lenses (IOLs) provide protection against potential blue light toxicity without significantly affecting clinical functioning of recipients, said James D. McCulley, MD, during a spotlight session on pseudophakic IOLs.
Lux to develop corneal rejection prevention implant
November 8th 2006Lux Biosciences has entered into an exclusive worldwide license agreement with the US National Institutes of Health (NIH) to acquire intellectual property rights for a cyclosporine A (CsA) eluting silicone matrix ocular implant, LX201. The candidate is to be tested for the prevention of rejection following corneal transplantation.